Background The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is
generally poor. Recently, new classes of drugs (eg immune checkpoint inhibitors and small …

The 10-year survival rate for patients with metastatic melanoma is less than 10%. Although
surgery and radiation therapy have a role in the treatment of metastatic disease, systemic …

For the past 40 years, various forms of interferon (IFN) have been evaluated as therapy in a
number of malignant and non-malignant diseases. With the advent of gene cloning, large …

This first German evidence-based guideline for cutaneous melanoma was developed under
the auspices of the German Dermatological Society (DDG) and the Dermatologic …

We undertook a systematic review of 41 randomised studies in disseminated melanoma,
identified by a comprehensive search. We aimed to investigate rates of response to various …

Quality of life (QL) scores may be used to assess the impact of disease and treatment, and to
predict survival of cancer patients in prospective clinical trials. The aim of this study was to …

Purpose To assess the effect of adding interferon-α (IFN)±interleukin-2 (IL-2) to
chemotherapy in patients with metastatic melanoma. Methods A published data meta …

Summation Cancer immunotherapy consists of approaches that modify the host immune
system, and/or the utilization of components of the immune system, as cancer treatment …

BACKGROUND: Advanced melanomas (non-resectable Stage-III/IV) are fatal, with few
effective treatments. It remains unclear if other drugs offer improvements over the standard …

The treatment of advanced cutaneous melanoma remains disappointing. Single-agent
cytotoxic drugs usually produce response rates of less than 20%, though newer agents …